BioSpace News Archive

Genprex, today announced that data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany.

Rafa Laboratories LTD. was awarded a follow-on production agreement for a total value of over $45 million from the Defense Department’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Glooko Inc. (“Glooko”), today announced that they have entered into a partnering agreement with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform.

Covalon Technologies Ltd. today announced its first quarter fiscal 2023 results for the period ended December 31, 2022.

CTI BioPharma Corp. today announced that its fourth quarter and full year 2022 financial results will be reported on Monday, March 6, 2023, after the close of the financial market.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the advancement of two investigational new drug candidates, ADX‑246 and ADX‑248, to clinical testing, pending completion of U.S. Food and Drug Administration Investigational New Drug (IND) requirements.

Xeris Biopharma Holdings, Inc. today announced that the Company will release its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, March 8, 2023.

Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.

MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. announced today that the companies entered into a definitive merger agreement for an all-stock transaction forming a company combining the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.

Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022.